| pubmed-article:18423782 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18423782 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:18423782 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:18423782 | lifeskim:mentions | umls-concept:C0684249 | lld:lifeskim |
| pubmed-article:18423782 | lifeskim:mentions | umls-concept:C0920317 | lld:lifeskim |
| pubmed-article:18423782 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:18423782 | lifeskim:mentions | umls-concept:C1122962 | lld:lifeskim |
| pubmed-article:18423782 | lifeskim:mentions | umls-concept:C1708063 | lld:lifeskim |
| pubmed-article:18423782 | lifeskim:mentions | umls-concept:C0015631 | lld:lifeskim |
| pubmed-article:18423782 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:18423782 | lifeskim:mentions | umls-concept:C1514162 | lld:lifeskim |
| pubmed-article:18423782 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:18423782 | pubmed:dateCreated | 2008-11-10 | lld:pubmed |
| pubmed-article:18423782 | pubmed:abstractText | To evaluate the risk/benefit profiles of gefitinib in comparison with platinum-based doublets chemotherapy as a first-line treatment for chemonaïve patients with advanced non-small-cell lung cancer in East Asia. | lld:pubmed |
| pubmed-article:18423782 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18423782 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423782 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18423782 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423782 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423782 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423782 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18423782 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18423782 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:18423782 | pubmed:issn | 0169-5002 | lld:pubmed |
| pubmed-article:18423782 | pubmed:author | pubmed-author:YangPan-ChyrP... | lld:pubmed |
| pubmed-article:18423782 | pubmed:author | pubmed-author:ChanK... | lld:pubmed |
| pubmed-article:18423782 | pubmed:author | pubmed-author:OravE JohnEJ | lld:pubmed |
| pubmed-article:18423782 | pubmed:author | pubmed-author:KurthTobiasT | lld:pubmed |
| pubmed-article:18423782 | pubmed:author | pubmed-author:ChenKuan-YuKY | lld:pubmed |
| pubmed-article:18423782 | pubmed:author | pubmed-author:ChangChia-Hsu... | lld:pubmed |
| pubmed-article:18423782 | pubmed:author | pubmed-author:Young-XuYinon... | lld:pubmed |
| pubmed-article:18423782 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18423782 | pubmed:volume | 62 | lld:pubmed |
| pubmed-article:18423782 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18423782 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18423782 | pubmed:pagination | 242-52 | lld:pubmed |
| pubmed-article:18423782 | pubmed:meshHeading | pubmed-meshheading:18423782... | lld:pubmed |
| pubmed-article:18423782 | pubmed:meshHeading | pubmed-meshheading:18423782... | lld:pubmed |
| pubmed-article:18423782 | pubmed:meshHeading | pubmed-meshheading:18423782... | lld:pubmed |
| pubmed-article:18423782 | pubmed:meshHeading | pubmed-meshheading:18423782... | lld:pubmed |
| pubmed-article:18423782 | pubmed:meshHeading | pubmed-meshheading:18423782... | lld:pubmed |
| pubmed-article:18423782 | pubmed:meshHeading | pubmed-meshheading:18423782... | lld:pubmed |
| pubmed-article:18423782 | pubmed:meshHeading | pubmed-meshheading:18423782... | lld:pubmed |
| pubmed-article:18423782 | pubmed:meshHeading | pubmed-meshheading:18423782... | lld:pubmed |
| pubmed-article:18423782 | pubmed:meshHeading | pubmed-meshheading:18423782... | lld:pubmed |
| pubmed-article:18423782 | pubmed:meshHeading | pubmed-meshheading:18423782... | lld:pubmed |
| pubmed-article:18423782 | pubmed:meshHeading | pubmed-meshheading:18423782... | lld:pubmed |
| pubmed-article:18423782 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18423782 | pubmed:articleTitle | The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis. | lld:pubmed |
| pubmed-article:18423782 | pubmed:affiliation | Department of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan. | lld:pubmed |
| pubmed-article:18423782 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18423782 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:18423782 | pubmed:publicationType | Meta-Analysis | lld:pubmed |
